MX2021000014A - Derivados de quinazolina tipo eter biarilico. - Google Patents
Derivados de quinazolina tipo eter biarilico.Info
- Publication number
- MX2021000014A MX2021000014A MX2021000014A MX2021000014A MX2021000014A MX 2021000014 A MX2021000014 A MX 2021000014A MX 2021000014 A MX2021000014 A MX 2021000014A MX 2021000014 A MX2021000014 A MX 2021000014A MX 2021000014 A MX2021000014 A MX 2021000014A
- Authority
- MX
- Mexico
- Prior art keywords
- sup
- type
- quinazoline derivative
- biaryl ether
- exon
- Prior art date
Links
- 125000005841 biaryl group Chemical group 0.000 title 1
- 125000002294 quinazolinyl group Chemical class N1=C(N=CC2=CC=CC=C12)* 0.000 title 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000037431 insertion Effects 0.000 abstract 2
- 238000003780 insertion Methods 0.000 abstract 2
- 230000035772 mutation Effects 0.000 abstract 2
- 102000020233 phosphotransferase Human genes 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 abstract 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 abstract 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 abstract 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018127829 | 2018-07-04 | ||
| PCT/JP2019/026483 WO2020009156A1 (ja) | 2018-07-04 | 2019-07-03 | ビアリールエーテル型キナゾリン誘導体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021000014A true MX2021000014A (es) | 2021-03-09 |
Family
ID=69059535
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021000014A MX2021000014A (es) | 2018-07-04 | 2019-07-03 | Derivados de quinazolina tipo eter biarilico. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20230025510A1 (https=) |
| EP (1) | EP3822263A4 (https=) |
| JP (1) | JP7288904B2 (https=) |
| KR (1) | KR20210029165A (https=) |
| CN (1) | CN112334460A (https=) |
| AU (1) | AU2019297889A1 (https=) |
| BR (1) | BR112020027064A2 (https=) |
| CA (1) | CA3105602A1 (https=) |
| CO (1) | CO2021000800A2 (https=) |
| IL (1) | IL279858A (https=) |
| MX (1) | MX2021000014A (https=) |
| PH (1) | PH12021550003A1 (https=) |
| SG (1) | SG11202013218QA (https=) |
| TW (1) | TW202012391A (https=) |
| WO (1) | WO2020009156A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020262998A1 (ko) * | 2019-06-26 | 2020-12-30 | 한미약품 주식회사 | 항 종양 활성을 갖는 신규 퀴나졸린 유도체 및 이를 포함하는 약학 조성물 |
| US20230271936A1 (en) * | 2020-08-10 | 2023-08-31 | Abbisko Therapeutics Co., Ltd | Efgr inhibitor, preparation method therefor and application thereof |
| WO2022105908A1 (zh) * | 2020-11-23 | 2022-05-27 | 上海和誉生物医药科技有限公司 | Egfr抑制剂及其制备方法与在药学上的应用 |
| CN113264888A (zh) * | 2021-03-04 | 2021-08-17 | 江苏康可得生物技术股份有限公司 | 酪氨酸激酶抑制剂及其药物应用 |
| KR20230156767A (ko) * | 2021-03-19 | 2023-11-14 | 베이징 사이텍-엠큐 파마슈티컬즈 리미티드 | 퀴나졸린계 화합물, 조성물 및 퀴나졸린계 화합물의 적용 |
| EP4323356A1 (en) | 2021-04-13 | 2024-02-21 | Nuvalent, Inc. | Amino-substituted heterocycles for treating cancers with egfr mutations |
| US20250136595A1 (en) * | 2022-02-09 | 2025-05-01 | Enliven Inc. | Acylated heterocyclic quinazoline derivatives as inhibitors of erbb2 |
| TW202404590A (zh) * | 2022-04-05 | 2024-02-01 | 美商纜圖藥品公司 | Ｅｇｆｒ抑制劑 |
| CN117384162A (zh) * | 2022-05-17 | 2024-01-12 | 浙江文达医药科技有限公司 | 选择性her2抑制剂 |
| WO2025167927A1 (zh) * | 2024-02-05 | 2025-08-14 | 苏州韬略生物科技股份有限公司 | 三取代喹唑啉衍生物及其酸加成盐及其药物组合物和用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU228446B1 (en) * | 1996-04-12 | 2013-03-28 | Warner Lambert Co | Kinazoline derivatives as irreversible inhibitors of protein-kinase, pharmaceutical compositions containing these compounds and use thereof |
| CA2527017A1 (en) * | 2003-05-27 | 2004-12-09 | Pfizer Products Inc. | Quinazolines and pyrido [3,4-d] pyrimidines as receptor tyrosine kinase inhibitors |
| TWI377944B (en) * | 2007-06-05 | 2012-12-01 | Hanmi Holdings Co Ltd | Novel amide derivative for inhibiting the growth of cancer cells |
| WO2013173254A1 (en) * | 2012-05-14 | 2013-11-21 | Dawei Zhang | Bicyclic compounds as kinases inhibitors |
| CN103965120B (zh) * | 2013-01-25 | 2016-08-17 | 上海医药集团股份有限公司 | 喹啉及喹唑啉衍生物、制备方法、中间体、组合物及应用 |
| MA46852A (fr) | 2016-11-17 | 2019-09-25 | Univ Texas | Composés à activité antitumorale contre des cellules cancéreuses porteuses de mutations egfr ou her2 exon 20 |
| WO2020262998A1 (ko) * | 2019-06-26 | 2020-12-30 | 한미약품 주식회사 | 항 종양 활성을 갖는 신규 퀴나졸린 유도체 및 이를 포함하는 약학 조성물 |
-
2019
- 2019-07-02 TW TW108123293A patent/TW202012391A/zh unknown
- 2019-07-03 WO PCT/JP2019/026483 patent/WO2020009156A1/ja not_active Ceased
- 2019-07-03 CA CA3105602A patent/CA3105602A1/en active Pending
- 2019-07-03 JP JP2020529034A patent/JP7288904B2/ja active Active
- 2019-07-03 BR BR112020027064-4A patent/BR112020027064A2/pt not_active Application Discontinuation
- 2019-07-03 AU AU2019297889A patent/AU2019297889A1/en not_active Abandoned
- 2019-07-03 KR KR1020207038066A patent/KR20210029165A/ko not_active Withdrawn
- 2019-07-03 MX MX2021000014A patent/MX2021000014A/es unknown
- 2019-07-03 EP EP19830650.8A patent/EP3822263A4/en not_active Withdrawn
- 2019-07-03 CN CN201980044514.8A patent/CN112334460A/zh active Pending
- 2019-07-03 SG SG11202013218QA patent/SG11202013218QA/en unknown
- 2019-07-03 US US17/257,238 patent/US20230025510A1/en not_active Abandoned
-
2020
- 2020-12-30 IL IL279858A patent/IL279858A/en unknown
-
2021
- 2021-01-03 PH PH12021550003A patent/PH12021550003A1/en unknown
- 2021-01-25 CO CONC2021/0000800A patent/CO2021000800A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PH12021550003A1 (en) | 2021-09-20 |
| IL279858A (en) | 2021-03-01 |
| AU2019297889A1 (en) | 2021-02-18 |
| EP3822263A1 (en) | 2021-05-19 |
| CA3105602A1 (en) | 2020-01-09 |
| JPWO2020009156A1 (ja) | 2021-07-15 |
| KR20210029165A (ko) | 2021-03-15 |
| CO2021000800A2 (es) | 2021-02-08 |
| WO2020009156A1 (ja) | 2020-01-09 |
| EP3822263A4 (en) | 2022-03-16 |
| SG11202013218QA (en) | 2021-02-25 |
| CN112334460A (zh) | 2021-02-05 |
| TW202012391A (zh) | 2020-04-01 |
| US20230025510A1 (en) | 2023-01-26 |
| JP7288904B2 (ja) | 2023-06-08 |
| BR112020027064A2 (pt) | 2021-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021000014A (es) | Derivados de quinazolina tipo eter biarilico. | |
| SA522431866B1 (ar) | مركبات بروتين-1 المتفاعل من المستقبل تثبيطية وطرق عملها واستخدامها | |
| PH12022551574A1 (en) | Egfr inhibitors | |
| MX2020007797A (es) | Inhibidores de la cinasa 2 de control general no desrepresible (gcn2) y usos de los mismos. | |
| MY209340A (en) | Egfr inhibitor for the treatment of cancer | |
| MX2016011112A (es) | Derivados de fenileno-1,5-diamina 2,4-disustituidos y aplicaciones de los mismos, composiciones farmacéuticas y composiciones farmaceuticamente aceptables preparadas de los mismos. | |
| MX2021005924A (es) | Compuestos y metodos de uso de los mismos para el tratamiento del cancer. | |
| AU2018271990A1 (en) | Covalent inhibitors of KRAS | |
| MY198690A (en) | Rip1 inhibitory compounds and methods for making and using the same | |
| TR201903322T4 (tr) | Kinaz inhibisyonu için heteroaril bileşikleri. | |
| WO2021011713A8 (en) | Imidazopyrimidines as eed inhibitors and the use thereof | |
| MX2021012423A (es) | Métodos y composiciones para degradación de proteínas específicas. | |
| CY1125335T1 (el) | Ετεροαρυλικες ενωσεις ως αναστολεας κινασης | |
| MX2019011116A (es) | Inhibidores de la tirosina quinasa de bruton. | |
| EP4001273A3 (en) | Aminopyrimidines as alk inhibitors | |
| JOP20190073A1 (ar) | مثبط انتقائي لمستقبل عامل نمو بشروي (egfr) لطافر إدخال exon 20 | |
| AU2019328154A8 (en) | Pyrazole compounds, pharmaceutical compositions thereof and use thereof | |
| PH12021553264A1 (en) | Pyrazolone and pyrimidine compound, and preparation method and use therefor | |
| MX2020008678A (es) | Metodos de uso para derivados de benzotriazol trisustituidos. | |
| CR20220255A (es) | Inhibidores de egfr | |
| EP3967694A4 (en) | 2, 4, 6-TRI-SUBSTITUTED PYRIMIDINE COMPOUND AS ATR-KINASE INHIBITOR | |
| CR20210181A (es) | Inhibidores de o-glicoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa | |
| CR20220004A (es) | Nuevos compuestos heterocíclicos | |
| NZ779146A (en) | Cyclic molecules as bruton’s tyrosine kinase inhibitor | |
| WO2018039077A8 (en) | Therapeutic compounds |